PDS 0101

Drug Profile

PDS 0101

Alternative Names: PDS 101; PDS0101; PDS0101A; PDS0101B; Versamune-HPV

Latest Information Update: 19 Apr 2016

Price : $50

At a glance

  • Originator PDS Biotechnology Corporation
  • Class Cancer vaccines; Papillomavirus vaccines; Peptide vaccines
  • Mechanism of Action Cytokine stimulants; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Cervical intraepithelial neoplasia

Most Recent Events

  • 13 Apr 2016 PDS Biotechnology completes a phase I trial in Cervical intraepithelial neoplasia in USA
  • 09 Feb 2016 PDS Biotechnology establishes CRADA with National Institutes of Health for the development of Versamune® platform in Human papillomavirus related cancer
  • 28 May 2015 PDS Biotechnology plans two phase II trials for cervical intra-epethelial neoplasia and cervical cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top